Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Brian Halliday
Job title: Academic Clinical Lecturer
Dr Halliday is a Senior Clinical Lecturer and BHF Intermediate Fellow at the National Heart and Lung Institute, Imperial College and Honorary Consultant Cardiologist at Royal Brompton Hospital, Guys’ and St Thomas’ NHS Trust. His research and clinical interests focus on the management of patients with cardiomyopathy and the use of cardiovascular magnetic resonance to improve treatment… View more
Cardiotoxicity in Breast Cancer: Challenges of Multimodal Therapies
Author(s): Daniel Lenihan , , , et al Start date: Jun 08, 2023

CV Disease in Special Populations
Author(s): Aarti Asnani , Randall T Peterson Added: 3 years ago
Survival rates among patients diagnosed with cancer have improved dramatically over the past few decades. In 2016, there were an estimated 16 million cancer survivors in the United States, a number expected to increase to 20 million over the subsequent decade.1 One-third of these patients will survive at least 5 years after their initial cancer diagnosis, largely due to cancer therapies that are… View more

Heart Failure

CV Disease in Special Populations
Cardiac Toxicity of Cancer Chemotherapy
Author(s): Aarti Asnani Start date: Aug 08, 2017

Heart Failure
Cardio-oncology A-Z: The Role of Big Data in Driving Cardio-oncology Forward
Author(s): Avirup Guha Added: 1 year ago
In this video we asked Dr Avirup Guha, Inaugural Director of Cardio-Oncology at Medical College of Georgia to summarise the topic of the role of big data in driving cardio-oncology forward. Dr. Guha’s research focuses are big data and cardio-oncology. Discussion Points 1. Relevance of big data in cardio-oncology 2. Big data questions already answered in cardio-oncology 3. Unanswered questions in… View more

Standards & Guidelines

Digital Health
ACC 22: Mavacamten in Patients with Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
Author(s): Milind Y Desai Added: 2 years ago
In this short summary interview, Dr Milind Y Desai (Cleveland Clinic, US) shares the findings from the VALOR-HCM trial (MyoKardia) (NCT04349072). This randomised, multicentre study was designed to assess the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy. Discussion… View more

Vascular Disease and Surgery
Author(s): Domenic A Sica Added: 3 years ago
A not inconsequential number of therapeutic agents or chemical substances can increase blood pressure (BP). The degree to which BP increases determines whether a specific definitional threshold has been crossed, at which time the patient is designated as having become hypertensive. Drugs that cause hypertension do so by either causing vasoconstriction, increasing extracellular fluid (ECF) volume,… View more

Prevention & Chronic Conditions
POTS-associated Conditions and Management Strategies
Author(s): Rebecca S Steinberg , Weston Dicken , Alexis Cutchins Added: 7 months ago

Demographic

Electrophysiology & Arrhythmia
Optimizing Clinical Outcomes in Acute Decompensated Heart Failure
Author(s): Sabu Thomas , Andrew J Boyle , Gary S Francis Added: 3 years ago
Acute decompensated heart failure (ADHF) is a syndrome defined by worsening fatigue, dyspnea, or edema that results from deteriorating heart function and usually leads to hospital admission or unscheduled medical intervention.1 Among patients over 65 years of age it remains the leading cause of hospital admission (>1 million admissions per year in the US alone), has an exceptionally high rate… View more

Heart Failure
Fontan-associated Liver Disease: A Practical Review
Author(s): Aleksandra Cieplucha , Werner Budts , Marc Gewillig , et al Added: 1 year ago

Heterogeneous Populations

CV Disease in Special Populations